Placebo controlled double-blind trial of fluvoxamine maleate in the obese

Abell, C. A.; Farquhar, Douglas R.; Galloway, Shaun; Steven, Fiona; Philip, A.E.; Munro, James

doi:10.1016/0022-3999(86)90043-7

Cited by 28 publications

(7 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Acute losses of 0.35 kg may be noted, but an average of 2–2.5 kg of weight may be gained [49]. Citalopram may cause 1 to 1.5 kg weight gain over a year's time [50, 51]. Fluvoxamine [5, 52] has two studies showing no weight gain and no weight loss.…”

Section: Weight Gain Due To Psychotropicsmentioning

confidence: 99%

Weight Gain, Obesity, and Psychotropic Prescribing

et al. 2011

View full text Add to dashboard Cite

A majority of psychiatric medications are known to generate weight gain and ultimately obesity in some patients. There is much speculation about the prevalence of weight gain and the degree of weight gain during acute and longitudinal treatment with these agents. There is newer literature looking at the etiology of this weight gain and the potential treatments being used to alleviate this side effect. The authors undertook a comprehensive literature review in order to present epidemiology, etiology, and treatment options of weight gain associated with antipsychotics, mood stabilizers, and antidepressants.

show abstract

Section: Weight Gain Due To Psychotropicsmentioning

confidence: 99%

Weight Gain, Obesity, and Psychotropic Prescribing

et al. 2011

View full text Add to dashboard Cite

show abstract

“…The first therapeutic strategies for BED were derived from either bulimia nervosa (BN), or from studies on the treatment of depressed obese patients [18][19][20]. As research progressively demonstrated substantial psychopathological differences, it became clear that a specific treatment strategy had to be considered [21].…”

Section: Introductionmentioning

confidence: 99%

Therapeutic options for binge eating disorder

Ramacciotti

Coli²,

Marazziti

et al. 2013

Eat Weight Disord

View full text Add to dashboard Cite

show abstract

“…Acute losses of 0.35 kg may be noted, but an average of 2–2.5 kg of weight may be gained [53]. Citalopram may cause 1–1.5 kg weight gain over a year's time [54,55]. Fluvoxamine [56,6] has two studies showing no weight gain and no weight loss.…”

Section: Introductionmentioning

confidence: 99%

Obesity and Psychotropics

Nihalani

Schwartz

Siddiqui

et al. 2011

CNS Neuroscience & Therapeutics

View full text Add to dashboard Cite

SUMMARYWeight gain is on the rise in the United States as is the diagnosis and treatment of mental disorders. These two phenomena are distinctly separate but tend to overlap in that most psychotropic agents approved for use in the United States are associated with the potential to induce weight gain. Metabolic disorders such as diabetes, hypercholesterolemia, and hypertension are also on the rise and often associated with weight gain and clearly associated with certain psychotropic medications. This article serves to provide a succinct review regarding the epidemiology, etiology, and treatment options for psychotropic-induced obesity.

show abstract

Placebo controlled double-blind trial of fluvoxamine maleate in the obese

Cited by 28 publications

References 7 publications

Weight Gain, Obesity, and Psychotropic Prescribing

Weight Gain, Obesity, and Psychotropic Prescribing

Therapeutic options for binge eating disorder

Obesity and Psychotropics

Contact Info

Product

Resources

About